Ownership and insider activity for Centessa Pharmaceuticals plc (CNTA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease.
Price
| Price | $40.50 |
| Market Cap | $6.3B |
| Exchange | NASDAQ |
| Country | GB |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-24 | Medicxi Ventures Management (Jersey) Ltd | S-Sale | 281,162 | $10.7M |
| 2026-06-24 | INDEX VENTURES LIFE VI (JERSEY) L.P. | S-Sale | 149,421 | $5.7M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 5,500 | $209K |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 221,559 | $1.3M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 166,779 | $1.6M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 100,000 | $2.0M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 160,000 | $1.5M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 100,000 | $385K |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 170,000 | $1.4M |
| 2026-06-24 | HUSSAIN IQBAL J | D-Return | 175,000 | $3.0M |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.2M | $595.1M | $393.6M | $128.0M | $383.2M | $61.3M |
| Short-term Investments | 0 | 0 | 0 | $128.5M | $99.0M | $233.3M |
| Receivables | 0 | $16.8M | $26.7M | $39.1M | $45.3M | $60.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $11.2M | $628.8M | $437.7M | $315.1M | $536.4M | $367.9M |
| Property, Plant & Equipment | 0 | $162000 | $1.2M | $13.0M | $11.8M | $10.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.7M | $629.6M | $444.3M | $360.2M | $576.8M | $687.5M |
| Accounts Payable | $1.0M | $8.1M | $13.8M | $11.8M | $7.1M | $7.6M |
| Short-term Debt | $5.6M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $8.6M | $24.6M | $38.3M | $39.4M | $58.0M | $42.9M |
| Long-term Debt | 0 | $75.7M | $69.8M | $75.7M | $108.9M | $7.6M |
| Total Liabilities | $8.6M | $138.1M | $108.1M | $124.0M | $175.3M | $160.6M |
| Retained Earnings | -$23.8M | -$385.7M | -$601.9M | -$752.9M | -$988.7M | -$1.19B |
| Total Equity | $3.1M | $491.6M | $336.2M | $236.2M | $401.5M | $526.9M |
| Total Debt | $5.6M | $75.7M | $69.8M | $84.6M | $117.2M | $7.6M |
| Net Debt | -$1.6M | -$519.4M | -$323.8M | -$172.0M | -$365.0M | -$287.0M |
| Working Capital | $2.5M | $604.1M | $399.4M | $275.7M | $478.4M | $324.9M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 9.53 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 9.85 |
Profitability
| Return on Equity | -60.37% |
| Return on Invested Capital | -42.41% |
| Return on Assets | -39.05% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CGEM · CMPX · DSGN · EWTX · GLUE · IPSC · IVA
Explore sector: Healthcare · Biotechnology
More sections of CNTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks